KSD-101
Phase 1Biologic
KSD-101 is one of 86 biologic programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 1.
2
Indications
3
Total Trials
3
Active Trials
85
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
127 competitors in Clinical Trial
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Venclexta
AbbViePhase 3
Avelox
BayerPhase 3
Paraplatin
AAvyxa
Phase 3
Potassium Iodide
MMeda Pharmaceuticals
Phase 3
Opzelura
DDizal Pharmaceuticals
Phase 3
Ablysinol
CSL BehringPhase 3
Nascobal
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
Zejula
GGlaxo Dba Glaxosmithkline
Phase 2
JOINTSTEM
RR-Bio
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Nasopharyngeal Carcinoma2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KSD-101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- KKousai Bio Co., Ltd.